Health Care & Life Sciences

Biopharma & Medical Device

Publications & Podcasts

August 27, 2020 Alerts and Newsletters

News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

June 18, 2020 Alerts and Newsletters

FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

June 12, 2020 Alerts and Newsletters

FDA Announces New Updates to its Guidance on Conducting Clinical Trials During COVID-19 and Notes Availability of its COVID MyStudies App

March 19, 2020 Alerts and Newsletters

COVID-19 Expanded Access Template

January 15, 2020 Alerts and Newsletters

More Proposed Changes to CCPA Geared to Health Care and Life Sciences Industries

October 25, 2019 Alerts and Newsletters

Proposed Regulations Under the CCPA Provide Some Clarity, But Questions Remain

July 30, 2019 Alerts and Newsletters

Massachusetts Budget Update: Commonwealth Now Waiting on Governor Baker

February 19, 2019 Alerts and Newsletters

OIG Proposes Revisions to Anti-Kickback Safe Harbor Regulations Affecting Prescription Drug Rebates

February 11, 2019 Alerts and Newsletters

Governor Baker’s 2020 Budget Would Allow MassHealth Authority to Negotiate Supplemental Rebates with Pharmaceutical Companies

January 10, 2019 Alerts and Newsletters

One Month Left to Submit Comments on HIPAA Request for Information

January 10, 2019 Alerts and Newsletters

Is Cybersecurity on Your 2019 Work Plan?

October 31, 2018 Alerts and Newsletters

Tag, You’re It: FDA Issues Guidance Ahead of Revisions to its Human Subjects Protection Regulations

Firm Highlights

Annual Update: The Legal Year in Review

More details coming soon!

Catch-Up Contributions: IRS Provides Relief from Roth Requirements of SECURE 2.0

On August 25, 2023, the IRS issued IRS Notice 2023-62 , providing much needed relief for employers who have been struggling to implement Section 603 of the SECURE 2.0 Act of 2022 (“SECURE 2.0&rdquo...

Publication/Podcast

Corporate Transparency Act regulations will go into effect soon and will affect almost all startup companies

On August 18, the Maine Venture Fund published an article by Verrill Partner Gregory Fryer, “Corporate Transparency Act regulations will go into effect soon and will affect almost all startup companies.” In the article...

82 Verrill Attorneys Recognized by Best Lawyers® 2024, Including 10 Named Lawyers of the Year

How AI Can Alter Skill Contests

AI could very well be today’s “Modern Prometheus” in the world of skill contests. Earlier this year, the AI-generated photograph “The Electrician” was a finalist in the World Photograph Organization’s Sony World Photograph Awards...

Publication/Podcast

No Longer a Walk In The Park -- Entity Formation Under the U.S. Corporate Transparency Act

Presently, forming a corporation, LLC, or other entity in the U.S. can be done on a largely anonymous basis, without naming its owners and with only limited disclosures about managers, officers, and directors. Under...

Successful Representation of Insurer before U.S. District Court for the District of Maine

Verrill successfully represented an insurer before the U.S. District Court for the District of Maine in an insurance coverage matter alleging that the insurer improperly denied a defense and indemnification to a landlord under...

Gratitude for Anya Endsley

Elections and Constitutional Law: Successfully Challenged Certification of Initiative Petition

In a victory for consumers and the ride-hailing public, the Massachusetts Supreme Judicial Court recently barred the Secretary of State from placing on the November ballot initiative petitions proposed by companies such as Uber...

Conducting Workplace Investigations

Join Verrill’s Erik Peters and Elizabeth Johnston on Wednesday, October 18, for Conducting Workplace Investigations. When and why should you open an investigation? Who is the best person to conduct it? Should you handle...

Contact Verrill at (855) 307 0700